Raptor Pharmaceutical Corp. RPTP shares dipped 38.2% to $7.43 following news that Phase 2b CyNCh trial did not meet primary endpoint. Share volume was 1.5 million, compared to an all-day average of 369,000
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
